The incidence and severity of Clostridium difficile-associated diarrhea (CDAD) has increased for the last fifteen years. Age is one of the main risk factor for Clostridium difficile infection (CDI); it is also associated with adverse outcomes (death, complicated course or recurrence). CDI treatment is based on general measures to reduce transmission, contributing factors elimination and antibiotic stewardship. Antibiotic therapy depends on CDI severity, number of previous episodes and risk factors of recurrence. Three molecules are currently available: metronidazole, vancomycin and fidaxomicin. Non-drug strategies such as fecal microbiota transplantation can be proposed to patients with multiple recurrences.